These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 27090944)

  • 61. Histone Acetylation and Its Modifiers in the Pathogenesis of Diabetic Nephropathy.
    Li X; Li C; Sun G
    J Diabetes Res; 2016; 2016():4065382. PubMed ID: 27379253
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Histone deacetylases as regulators of inflammation and immunity.
    Shakespear MR; Halili MA; Irvine KM; Fairlie DP; Sweet MJ
    Trends Immunol; 2011 Jul; 32(7):335-43. PubMed ID: 21570914
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents.
    Mottamal M; Zheng S; Huang TL; Wang G
    Molecules; 2015 Mar; 20(3):3898-941. PubMed ID: 25738536
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Targeting histone deacetylase in thyroid cancer.
    Russo D; Durante C; Bulotta S; Puppin C; Puxeddu E; Filetti S; Damante G
    Expert Opin Ther Targets; 2013 Feb; 17(2):179-93. PubMed ID: 23234477
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Epigenetics in vascular disease - therapeutic potential of new agents.
    Xu SS; Alam S; Margariti A
    Curr Vasc Pharmacol; 2014 Jan; 12(1):77-86. PubMed ID: 22724461
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Phenylbutyrate and β-cell function: contribution of histone deacetylases and ER stress inhibition.
    Khan S; Komarya SK; Jena G
    Epigenomics; 2017 May; 9(5):711-720. PubMed ID: 28470097
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Epigenetics in osteoarthritis: Potential of HDAC inhibitors as therapeutics.
    Khan NM; Haqqi TM
    Pharmacol Res; 2018 Feb; 128():73-79. PubMed ID: 28827187
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Histone deacetylases as targets for the treatment of human neurodegenerative diseases.
    D'Mello SR
    Drug News Perspect; 2009 Nov; 22(9):513-24. PubMed ID: 20072728
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Therapeutic Approaches to Histone Reprogramming in Retinal Degeneration.
    Berner AK; Kleinman ME
    Adv Exp Med Biol; 2016; 854():39-44. PubMed ID: 26427391
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Histone deacetylases in kidney development: implications for disease and therapy.
    Chen S; El-Dahr SS
    Pediatr Nephrol; 2013 May; 28(5):689-98. PubMed ID: 22722820
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Regulation of Central Nervous System Development by Class I Histone Deacetylases.
    D'Mello SR
    Dev Neurosci; 2019; 41(3-4):149-165. PubMed ID: 31982872
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The role of histone deacetylases in inflammatory respiratory diseases: an update.
    Pan S; Wang X; Jiao J; Zhang L
    Expert Rev Clin Immunol; 2024 Oct; 20(10):1193-1203. PubMed ID: 38823008
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Histone Acetylation Modifiers in the Pathogenesis of Alzheimer's Disease.
    Lu X; Wang L; Yu C; Yu D; Yu G
    Front Cell Neurosci; 2015; 9():226. PubMed ID: 26136662
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Epigenetic suppression of GAD65 expression mediates persistent pain.
    Zhang Z; Cai YQ; Zou F; Bie B; Pan ZZ
    Nat Med; 2011 Oct; 17(11):1448-55. PubMed ID: 21983856
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Zinc-dependent deacetylases (HDACs) as potential targets for treating Alzheimer's disease.
    Li Y; Lin S; Gu Z; Chen L; He B
    Bioorg Med Chem Lett; 2022 Nov; 76():129015. PubMed ID: 36208870
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Histone deacetylases govern cellular mechanisms underlying behavioral and synaptic plasticity in the developing and adult brain.
    Morris MJ; Karra AS; Monteggia LM
    Behav Pharmacol; 2010 Sep; 21(5-6):409-19. PubMed ID: 20555253
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Advances in the Development of PET Ligands Targeting Histone Deacetylases for the Assessment of Neurodegenerative Diseases.
    Tago T; Toyohara J
    Molecules; 2018 Jan; 23(2):. PubMed ID: 29385079
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Function of histone deacetylase inhibitors in inflammation.
    Grabiec AM; Tak PP; Reedquist KA
    Crit Rev Immunol; 2011; 31(3):233-63. PubMed ID: 21740352
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Directing cell differentiation with small-molecule histone deacetylase inhibitors: the example of promoting pancreatic endocrine cells.
    Haumaitre C; Lenoir O; Scharfmann R
    Cell Cycle; 2009 Feb; 8(4):536-44. PubMed ID: 19197155
    [TBL] [Abstract][Full Text] [Related]  

  • 80. HDAC inhibitors and immunotherapy; a double edged sword?
    Kroesen M; Gielen P; Brok IC; Armandari I; Hoogerbrugge PM; Adema GJ
    Oncotarget; 2014 Aug; 5(16):6558-72. PubMed ID: 25115382
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.